Comparing Different Non-invasive Methods in Assessment of the Effects of Curcumin on Hepatic Fibrosis in Patients with Non-alcoholic Fatty Liver Disease
Gastroenterology and Hepatology from Bed to Bench,
Vol. 11 No. Supplement 1 (2018),
11 December 2018
,
Page s8-s13
https://doi.org/10.22037/ghfbb.v0i0.1435
Abstract
Aim: The aim of this study was to examine the effects of curcumin supplementation on hepatic fibrosis using different fibrosis assessment methods.
Background: Nonalcoholic fatty liver disease (NAFLD) may progress to hepatic fibrosis. Detection of hepatic fibrosis should be measured by liver biopsy, which is an invasive method. Thus, some non-invasive methods are suggested.
Methods: Hepatic fibrosis was evaluated in forty six patients with NAFLD before and three months after supplementation with 1.5 gram curcumin or placebo. Methods of assessments included fibroscan, and calculating non-invasive marker panel including FIB-4 (Fibrosis4), NFS (NAFLD fibrosis score), APRI (AST (Aspartate aminotransferase) Platelet Ratio Index), and BARD (body mass index, AST/ALT (Alanine aminotransferase ratio, diabetes).
Results: Fibrosis score was reduced significantly after curcumin supplementation using fibroscan (p<0.01), FIB-4 (p<0.05) and APRI (p<0.05) tests, while fibrosis score did not change significantly using BARD and NFS methods (p>0.05).
Conclusion: Our results revealed that fibroscan, FIB-4, and APRI are similar in assessment of hepatic fibrosis changes after curcumin supplementation. Future studies with higher sample sizes are needed to confirm these results.
Keywords: Curcumin, Hepatic Fibrosis, NAFLD.
(Please cite as: Saadati S, Hekmatdoost A, Hatami B, Mansour A, Yari Z, Hedayati M, et al. Comparing different non-invasive methods in assessment of the effects of curcumin on hepatic fibrosis in patients with non-alcoholic fatty liver disease Gastroenterol Hepatol Bed Bench 2018;11(Suppl. 1):S8-S13).
- Fibrosis
- Fibroscan
- non-invasive marker plan
- fatty liver
How to Cite
References
Aron‐Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non‐alcoholic fatty liver disease: new insights. CMI 2013;19:338-48.
Juan Pablo Arab, Marco Arrese, and Michael Trauner. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Annu Rev Pathol Mech Dis 2018;13:321–50.
Robert W.Hu, Elizabeth J.carey, Keith D.Lindor, James H. Tabibian. Curcumin in hepatobiliary disease: Pharmacotherapeutic properties and emerging potential clinical applications. Concise Review. Ann Hepatol 2017;16: 835-841.
Nabavi SF, Daglia M, Moghaddam AH, Habtemariam S, Nabavi SM. Curcumin and liver disease: fromchemistry to medicine. CRFSFS 2014;13:62-77.
Karbalaei R, Piran M, Rezaei-Tavirani M, Asadzadeh-Aghdaei H, Heidari MH. A systems biology analysis protein-protein interaction of NASH and IBD based on comprehensive gene information. Gastroenterol Hepatol Bed Bench. 2017;10:194-201.
Riccardo BA, Riccardo S, Salvatore N, Michele A, Andrea S, Maria MA, et al. The role of Curcumin in liver diseases. Arch Med Sci. Riccardo B, Riccardo S, Salvatore N, Michele A, Andrea S, Maria M et al. The role of curcumin in liver diseases. Archives of Medical Science. 2018. doi:10.5114/aoms.2018.73596.
Tang Y. Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo. Dig Dis Sci. 2015;60:1554-64.
Tang Y. Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo. Dig Dis Sci 2015:1554-64.
Tapper EB, Sengupta N, Hunink MG, Afdhal NH, Lai M. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. Am J Gastroenterol 2015;110:1298-304.
Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 2014;384:1953-97.
Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of non‐alcoholic fatty liver disease with curcumin: a randomized placebo‐controlled trial. Phytother Res 2016;30:1540-8.
Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Curcumin lowers serum lipids and uric acid in subjects with non-alcoholic fatty liver disease: a randomized controlled trial. J Cardiovasc Pharmacol 2016;68:223-9.
Seung-Joo J, Min BW, Park H. Protective Effects of curcumin on CCl4-induced hepatic fibrosis with high fat diet in C57BL/6 mice. Korean J Clin Lab Sci 2015; 47: 251-258.
Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-54.
Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatol 2007;46:32-6.
Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-7.
Calès P, Lainé F, Boursier J, Deugnier Y, Moal V, Oberti F, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009;50:165-73.
Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013;167:1109-17.
Yilmaz Y, Yesil A, Gerin F, Ergelen R, Akin H, Celikel ÇA, et al. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. Scand J Gastroentero 2014;49:611-6.
Lédinghen V, Vergniol J, Foucher J, Merrouche W, Bail B. Non‐invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012;32:911-8.
Sun W, Cui H, Li N, Wei Y, Lai S, Yang Y, et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study. Hepatol Res. 2016;46:862-70.
Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Gra-Oramas B, Gonzalez-Fabian L, Lazo-Del Vallin S, et al. Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH. Liver Int. 2017;37(12):1887-1896.
- Abstract Viewed: 134 times
- PDF Downloaded: 136 times